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Abstract
The balance between vascular oxygen supply and metabolic demand for oxygen within 
the vasculature is normally tightly regulated. An imbalance leads to hypoxia and a con-
sequential cascade of cellular signals that attempt to offset the effects of hypoxia. Hypoxia 
is invariably associated with atherosclerosis, wound repair, inflammation and vascular 
disease. The anoxaemia hypothesis proposes that an imbalance between the demand for 
and supply of oxygen in the arterial wall is a key factor in the development of atheroscle-
rosis and plaque angiogenesis. There is now substantial evidence that hypoxia plays an 
essential role in angiogenesis as well as plaque angiogenesis. It controls the metabolism, 
and responses of many of the cell types found within the developing plaque and whether 
the plaque will evolve into a stable or unstable phenotype. Hypoxia is characterized in 
molecular terms by the stabilization of hypoxia-inducible factor (HIF) 1a, a subunit of 
the heterodimeric nuclear transcriptional factor HIF-1 and a master regulator of oxygen 
homeostasis. The expression of HIF-1 is localized to perivascular tissues, inflammatory 
macrophages and smooth muscle cells where it regulates several genes that are impor-
tant to vascular function including vascular endothelial growth factor, nitric oxide syn-
thase, endothelin-1 and erythropoietin. This chapter summarizes the effects of hypoxia 
on the functions of cells involved in angiogenesis as well as atherogenesis (plaque angio-
genesis) and the evidence for its potential importance from experimental models and 
clinical studies.
Keywords: hypoxia, HIF-1, proliferation, atherosclerosis, plaque formation, blood 
vessel
1. Introduction
The circulatory system develops early in mammalian embryogenesis. An oxygen supply is 
essential for normal tissue function, development and homeostasis. The vascular network 
within the cardiovascular system is essential for the delivery of oxygen, nutrients and other 
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molecules to the tissues of the body [1]. Oxygen availability serves as an important regulator 
of the cardiovascular system. Oxygen balance may be perturbed if there is reduced oxygen 
diffusion, or increased oxygen consumption that may be a consequence of rapid cellular divi-
sion during embryonic development, by tumour growth, or by vasculature dysfunction due 
to vessel occlusion or rupture [2].
Hypoxia is defined by a reduced oxygen tension relative to those normally extant within a 
particular tissue. It has multiple impacts on the vascular system and cell function [3]. The 
effects of moderate hypoxia (3–5% O2) are usually reversible and are usually accompanied by 
adaptive physiological responses in the cells. A lower oxygen tension (0–1% O2) contributes 
to the pathophysiology of tumour progression and cell apoptosis [4] and is a feature of condi-
tions that include cancer, ischemic heart disease, peripheral artery disease, wound healing 
and neovascular retinopathy. Hypoxia promotes vessel growth by stimulating an upregula-
tion of multiple proangiogenic pathways that mediate key aspects of endothelial, stromal 
and vascular support cell biology. The role of hypoxia in human disease is now becoming 
increasingly clear [5] including the association between hypoxia and endothelial dysfunction 
that affects several cellular processes and signal transduction.
Hypoxia can occur in several ways: (1) hypoxic hypoxia is caused by an insufficient oxygen 
concentration in the air in the lungs, which may occur during sleep apnea, when the diffusion 
of oxygen to the blood is reduced, or at high altitude; (2) hypoxemic hypoxia occurs when the 
blood has reduced transport capacity as seen in carbon monoxide poisoning when haemo-
globin cannot carry oxygen at its normal concentrations; (3) stagnant hypoxia results when 
the cardiac output does not match the demands of the body and the flow is not sufficient to 
deliver enough oxygenated blood to the tissue and (4) histotoxic hypoxia occurs when cells 
cannot utilize the available oxygen, for example following cyanide poisoning when oxygen 
cannot be used to produce ATP as the mitochondrial electron transport is inhibited.
Chronic tissue hypoxia (an oxygen tension of 2–3% for a prolonged period of time) may cause 
uncontrolled proliferation of cells. When physiological oxygen concentrations are restored, 
the increased blood flow supplies excessive oxygen; this may then lead to increased free-
radical generation, tissue damage and concomitant activation of stress-response genes; a con-
dition known as ‘reoxygenation injury’. In these circumstances, normal cells/tissues may not 
survive; but tumour cells are still able to proliferate despite the hypoxic milieu, as they have 
developed genetic and adaptive changes leading to resistance to hypoxia [6].
Hypoxia also plays important roles in normal human physiology and development; for exam-
ple, it is integral to normal embryonic development. Whatever the cause, or the severity of 
hypoxia, it leads to an induction of adaptive responses within the endothelial and vascular 
smooth muscle cells through the activation of genes that participate in angiogenesis, cell pro-
liferation/survival and in glucose and iron metabolism [7].
In healthy vascular tissue, vascular smooth muscle cells (SMCs) and endothelial cells (ECs) 
proliferate at very low levels. However, SMCs and ECs can be stimulated to re-enter the cell 
cycle in response to several physiological and pathological stimuli. Hypoxia is considered an 
important stimulus of SMC and EC proliferation and is found in atherosclerotic lesions and 
rapidly growing tumours [4].
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The proliferation of ECs is pivotal to the formation of new micro-vessels and is important 
during organ development in embryogenesis and tumour growth, and also contributes to 
diabetic retinopathy, psoriasis, rheumatoid arthritis and atherosclerosis. Abnormal SMC pro-
liferation contributes to atherosclerosis, intimal hyperplasia after angioplasty and graft ath-
erosclerosis after coronary transplantation [8, 9].
2. Consequences of hypoxia
Most cells are able to survive under hypoxic conditions through the transcriptional activa-
tion of a series of genes. The oxygen-sensitive transcriptional activator, hypoxia-inducible 
factor-1 (HIF-1) is the key transcriptional mediator of the hypoxic response and master 
regulator of O2 homeostasis. It orchestrates the profound changes in cellular transcription 
that accompanies hypoxia by controlling the expression of numerous angiogenic, meta-
bolic and cell cycle genes. Accordingly, the HIF pathway is currently viewed as a master 
regulator of angiogenesis [5].
HIF-1 is normally only found in hypoxic cells. It is a heterodimer that is composed of an 
O2-regulated HIF-1α subunit and a constitutively expressed HIF-1β subunit [10]. In the 
α-subunit, there is an oxygen-dependent degradation (ODD) domain, where the 4-hydroxy-
proline formation is catalysed by proline-hydroxylase-2 (PHD-2). This leads to its ubiqui-
tination by the von Hippel-Lindau E3 ubiquitin ligase (VHL) and subsequent proteasomal 
degradation under normoxic cellular conditions. This prevents the formation of a functional 
HIF dimer [11]. Since PHDs require oxygen for their catalytic activity, and function as cellular 
oxygen sensors, HIF degradation only occurs under normoxic conditions. Factor inhibiting 
HIF-1 (FIH) protein, which hydroxylates HIF-1, also contributes to HIF-1 inactivation in nor-
moxic conditions, and thereby prevents the interaction of this subunit with the two transcrip-
tional co-activators of HIF-1: p300 and CREB-binding protein (CBP) which are essential for 
HIF-1 transcription. Expression and stabilization of the HIF-1 complex is regulated through 
feedback inhibition, as PHD-2 itself is activated by HIF-1 [12].
Under hypoxic conditions, HIF-1 protein is stable and active as a hydroxylase, VHL proteins, 
and FIH are all inhibited by a lack of oxygen. HIF-1 is then able to interact with its co-acti-
vators and can dimerize with its constitutively expressed β-subunit [12]. Once stabilized, the 
HIF-1 protein can bind to the regulatory regions of its target genes, inducing their expression; 
these target genes include VEGF (vascular endothelial growth factor) [13], erythropoietin [14] 
and nitric oxide synthase (NOS) [15, 16] and other proangiogenic factors such as PlGF (pla-
cental growth factor), or angiopoietins [12] (Figure 1).
It has been proposed that the induction of a pseudo-hypoxic response by inhibiting HIF pro-
lyl 4-hydroxylases may provide a novel therapeutic target in the treatment of hypoxia-asso-
ciated diseases [17].
Several small molecules, such as dimethyloxalyl glycine [18], Roxadustat (FG-4592) [19] and 
ZYAN1 [20], have been developed to inhibit prolyl hydroxylase domain-containing (PHD) 
enzymes, and cause HIF activation [21]. These agents have been applied to the treatment of 
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renal anaemia in which there is a deficiency of erythropoietin [22, 23]. The administration of 
these compounds is associated with an improved iron profile and an increase of endogenous 
erythropoietin production to near the physiological range. The clinical trials currently under-
way aim to address whether PHD enzyme inhibitors will improve clinical end-points, includ-
ing cardiovascular events [24]. PHD inhibitors have been reported to reduce blood pressure 
[22] and plasma cholesterol concentrations [19]. Hence, there is a good reason to believe that 
some PHD inhibitors will reduce cardiovascular endpoints in patients with renal disease. 
Whether they will benefit a broader category of patients with high risk of cardiovascular 
disease is difficult to predict.
Hydroxylase activity can be also rescued by mutating specific regions, or by adding cobalt 
ions to the cell, the latter of which presumably compete for iron-binding sites. Some hydroxy-
lases in the prolyl family can be selectively inhibited by Adriamycin in vitro. Cobalt (II) and 
nickel (II) ions increase HIF-1 activity in cells, presumably because these ions displace iron 
from the active sites of 2-oxo-glutarate (2OG) hydroxylases [12].
It has been shown that HIF-1α can be regulated by non-hypoxic stimuli such as lipopolysac-
charides (LPS), thrombin and angiotensin II (Ang II) [25]. Hormones such as angiotensin II 
and platelet-derived growth factor stimulate the HIF pathway by increasing HIF-1α protein 
levels through production of reactive oxygen species (ROS) within the cell. Although the exact 
mechanism for this is unclear, it appears to be entirely distinct from the hypoxia pathways.
Figure  1. Regulation of the hypoxia-inducible transcription factor (HIF-1α) pathway. Under normal oxygen tensions 
(normoxia), prolyl hydroxylase (PHD) enzymes, von Hippel-Lindau protein (pVHL), the ubiquitin ligase complex (Ub) 
and factor inhibiting HIF-1 (FIH) are active leading to HIF-1α proteasomal degradation. Under hypoxic conditions, 
PHD, pVHL and Ub are not active leading to its cytoplasmic accumulation of HIF-1α. The HIF-1α gene is transcribed in 
the nucleus with the help of specificity protein (Sp) 1, P300, and HIF-1β leading to transcription of HIF target genes such 
as EPO, NOS and VEGF (adapted from references and [65]).
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Thrombin and other growth factors appear to increase angiogenesis through HIF-1α protein 
agonist mechanisms. Insulin similarly activates HIF-1α through the action of multiple protein 
kinases necessary for expression and function. p53 is responsible for promoting ubiquitina-
tion of HIF-1α, and may be an another possible target for enhancing HIF-1. Homozygous 
deletion of the p53 gene has been found to cause HIF-1 activation [26]. Gene therapy may 
eventually be used to increase HIF-1 levels and relieve complications of ischemia. For exam-
ple, delivery of a stabilized, recombinant form of HIF-1α through adeno-associated virus 
(AAV) in order to overexpress HIF-1 has been shown to result in significantly increased capil-
lary density in skeletal muscle [27]. While gene therapy approaches aimed at the process and 
effects of angiogenesis continue to be developed and studied, higher levels of success in pre-
clinical trials currently are being sought before clinical applications are pursued. Amongst the 
remaining obstacles in using gene therapy for this purpose is the effective mode of delivery 
[12]. Inhibition of PHD2 using siRNA has been shown to decrease cardiac infarction size in 
murine models [28, 29].
In addition to HIF-1α, there are two other members of HIF superfamily that have been 
described: HIF-2 and HIF-3 [30]. Both are important regulators of the hypoxia response 
with similar actions as HIF-1 [31] and lead to the transcriptional activation of target 
genes in hypoxia [32]. However, Eubank et al demonstrated opposing roles for the HIFs 
in tumour angiogenesis, with HIF-1 exhibiting proangiogenic properties that act through 
its effects on VEGF secretion, whereas HIF-2 exhibits anti-angiogenic activity by induc-
ing the production of the endogenous angiogenesis inhibitor, sVEGFR-1 [33]. HIF-3α has 
complementary functions, rather than redundant to HIF-1α induction in protection against 
hypoxic damage in alveolar epithelial cells in protection against hypoxic damage in alveo-
lar epithelial cells [34].
Although the oxygen-sensing mechanism involving oxygen-dependent hydroxylation of the 
HIF-α subunits is probably a universal mechanism in cells, and has been highly conserved 
during evolution, additional regulatory steps appear to determine which of the alternative 
subunits is induced [34]. One of the best studied hypoxic responses that will be discussed in 
this chapter is the induction of angiogenic factors and growth factors, which lead to the for-
mation and growth of new blood vessels.
3. Hypoxia and angiogenesis
Blood vessels formation occurs through two basic mechanisms: (1) vasculogenesis repre-
sents de novo formation of blood vessels, and is derived from endothelial progenitors and (2) 
angiogenesis and arteriogenesis (formation of blood vessels from pre-existing blood vessels).
Angiogenesis is a tightly regulated multi-step process that begins when cells within a tissue 
respond to hypoxia. When tissues grow beyond the physiological oxygen diffusion limit, the 
relative hypoxia triggers expansion of vascular beds by inducing angiogenic factors in the 
cells of the vascular beds, which are physiologically oxygenated by simple diffusion of oxy-
gen. Angiogenesis may be a physiological process, as in the case in embryonic development, 
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wound healing or vessel penetration into avascular regions. It may also be pathological, for 
example when it occurs during the formation of solid tumours, eye disease, chronic inflamma-
tory disorders such as rheumatoid arthritis, psoriasis and periodontitis and atherosclerosis.
The regulation of angiogenesis (whether in physiological or pathological cases) by hypoxia 
is an important component of homeostatic mechanisms that link vascular oxygen supply to 
metabolic demand. An understanding of the processes involved in angiogenic, the role of 
the interacting proteins involved, and how all this is regulated by hypoxia through an ever-
expanding number of pathways in multiple cell types may lead to the identification of novel 
therapies and modalities for ischemic vascular diseases as well as diseases characterized by 
excessive angiogenesis, such as rheumatoid arthritis, psoriasis, tumours, ischemic brain and 
heart attack [5, 6].
Angiogenesis in hypoxia is regulated by several pro- and anti-angiogenic factors [1]. HIF-1 
has been established as the major inducer of angiogenesis [35]. It regulates the transcription of 
VEGF, a major regulator of angiogenesis which promotes endothelial cell migration towards 
the hypoxic area. During hypoxia, HIF-1 binds to the regulatory region of the VEGF gene, 
inducing its transcription and initiating its expression. VEGF is then secreted and binds to 
cognate receptor tyrosine kinases (VEGFR1 and VEGFR2) located on the surface of vascular 
endothelial cells triggering a cascade of intracellular signalling pathways that initiate angio-
genesis [10]. These endothelial cells are recruited to form new blood vessels which ultimately 
supply the given area with oxygenated blood [12]. Interestingly, recent studies have shown 
that hypoxia influences additional aspects of angiogenesis, including vessel patterning, matu-
ration and function [5].
Other factors such as angiopoietin-2/angiopoietin-1 [36, 37], angiopoietin receptor (Tie2) [38], 
platelet-derived growth factor (PDGF) [39], basic fibroblast growth factor (bFGF) [40] and 
monocyte chemoattractant protein 1 (MCP-1) [41] have also been reported to be responsible 
not only for increasing vascular permeability, endothelial sprouting, maintenance, differen-
tiation and remodelling but also cell proliferation, migration, enhancement of endothelial 
assembly and lumen formation (Figure 2). In hypoxia, angiogenesis is also modulated by 
several factors that are secreted by leucocytes, which produce a high abundance of angiogenic 
factors, various interleukins such as TGF-β1 and MCP-1 and proteinases [42]. Thus, hypoxia 
provides an important environmental stimulus not only for angiogenesis but also for related 
phenomena in the hypoxic or surrounding area, suggesting that hypoxia is more than simply 
a regulator of angiogenesis [6].
Angiogenesis may be detrimental when it is excessive. Therefore, angiogenic factors must be 
highly active but also be tightly regulated. Angiogenesis that is associated with pathological 
consequences may exhibit differences in the responsible molecular pathways in comparison 
to physiological angiogenesis. Mutations in oncogenes and tumour suppressor genes and dis-
ruptions in growth factor activity play an important role in tumour angiogenesis. The activa-
tion of the most prominent proangiogenic factor VEGF might be due to physiological stimuli 
such as hypoxia or inflammation or due to oncogene activation and tumour suppression func-
tion loss. Physiological angiogenesis that occurs during embryonic development or wound 
healing seems to be dependent on VEGF signalling, whereas tumour angiogenesis adopts 
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Hypoxia, Angiogenesis and Atherogenesis 7
the ability to shift its dependence from VEGF to other proangiogenic pathways, for example, 
through the recruitment of myeloid cells and the upregulation of alternative vascular growth 
factors (PlGF and FGF) [1].
The identification of alternative ways of inhibiting tumour growth by disrupting the growth-
triggering mechanisms of increasing vascular supply through angiogenesis will depend on 
the understanding of how tumour cells develop their own vasculature. Other cofactors are 
essential to ensure maximum efficiency of the transcriptional machinery related to changes 
in oxygen availability within cells/tissues, and the roles of different HIFs in eliciting hypoxic 
responses seem to be more divergent as originally assumed. Chen et al. have shown new 
regulatory interactions of HIF-related mechanisms involving the interactions of basic HIFs, 
HIF-1α and HIF-2α with their regulatory binding proteins, histone deacetylase 7 (HDAC7) 
and translation initiation factor 6 (Int6), respectively [6]. Int6 induces HIF- 2 degradation. In 
addition, silencing of Int6 produces a potent, physiological induction of angiogenesis that 
may be useful in the treatment of diseases related to insufficient blood supply. The newly 
discovered binding proteins-HDAC7 for HIF-1 and Int6 for HIF-2 support the assumption 
that the 2 HIF isoforms play distinct roles in eliciting hypoxia-related responses. HIF-2 may 
be considered as one of the master switches for inducing angiogenic factors at least in some 
cell types [6].
The hypoxia/reoxygenation cycle leads to the formation of reactive oxygen species (ROS) 
that may subsequently regulate HIF-1 but in a rather complex manner. It has been suggested 
that ROS promote angiogenesis, either directly through stimulation of HIF-1 genes that are 
involved in stimulating angiogenesis, such as NOS and NADPH oxidase orthrough the gen-
eration of active oxidation products, including lipid peroxides. ROS are associated with the 
development of several chronic diseases that include atherosclerosis, type 2 diabetes mellitus, 
and cancer [43]. Although ROS have damaging effects on tissues, causing cell death at high 
concentrations, lesser degrees of oxidative stress may play a positive role during angiogene-
Figure  2. HIF-1α regulates factors involved in developmental and pathological angiogenesis. HIF-1α directly regulates 
genes involved in steps such as vasodilation, increased vascular permeability, extracellular matrix remodelling and 
proliferation.
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sis, or other pathophysiological processes. Angiogenesis induced by oxidative stress involves 
vascular endothelial growth factor (VEGF) signalling, although VEGF-independent pathways 
have also been identified [44].
The clinical importance of this biological process has become increasingly apparent over the 
last decade, and angiogenesis now represents a major focus for novel therapeutic approaches 
to the prevention and treatment of multiple diseases, most notably ischemic cardiovascular 
disease and cancer [10].
4. Atherosclerosis and plaque angiogenesis
Considering the important contributions of HIF-1 in angiogenesis, it may also be a promising 
target for treating ischaemic disease [1] and pressure-overload heart failure [45].
Atherosclerosis causes clinical disease through the occlusion of the arteries as a result of 
excessive build-up of plaque within the artery wall resulting from the accumulation of choles-
terol, fatty material and extracellular matrix. This causes obstruction in the blood flow to the 
myocardium (coronary heart disease), brain (ischemic stroke) or lower extremities (peripheral 
vascular). The most common of these manifestations is coronary heart disease that includes 
stable angina pectoris and the acute coronary syndromes [46].
Coronary heart disease (CHD) is a major cause of mortality globally (1 in every 6 deaths 
annually). An estimated £2bn per annum is used to treat CHD and its co-morbidities [47]. 
Arterial injury plays a key role in the initiation and progression of CHD [48]. Treatments 
for CHD range from lifestyle changes and non-invasive medical therapies to pharmacologi-
cal therapies and open surgical interventions. Despite the widespread use of drugs such as 
statins, there remains a significant proportion of individuals for whom response to therapy is 
sub-optimal, and who develop atherosclerosis [49, 50].
Atherosclerosis is a lipoprotein-driven disease affecting medium and large arteries that 
leads to plaque formation at specific sites of the arterial tree through intimal inflamma-
tion, necrosis, fibrosis and calcification. It is a chronic inflammatory process that involves 
increased oxidative stress, endothelial damage, and smooth muscle cell proliferation and 
migration. It is associated with several established risk factors, including hypertension, 
hyperglycaemia, ageing and dyslipidaemia [51]. It is important to control the factors 
involved in the progression of atherosclerosis because advanced atherosclerotic lesions are 
prone to rupture, leading to disability or death. Plaque at risk of rupture has been a major 
focus of research [52]. There is an emerging need for new therapies to stabilize athero-
sclerotic lesions. Further understanding of the effects of hypoxia in atherosclerotic lesions 
could indicate potential therapeutic targets [53, 54]. The presence of hypoxia in human 
carotid atherosclerotic lesions correlates with angiogenesis. Hypoxia plays a key role in 
the progression and development of advanced lesions by promoting lipid accumulation, 
increased inflammation, ATP depletion and angiogenesis. A recent study has convincingly 
demonstrated the presence of hypoxia in macrophage-rich regions of advanced human 
carotid atherosclerotic lesions [53].
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
Hypoxia, Angiogenesis and Atherogenesis 9
4.1. Evidence for hypoxia within atherosclerotic plaque
Hypoxia in atherosclerotic plaques is now widely recognized, because of the use of specific 
probes in imaging studies [4]. Imaging plaque hypoxia could provide a means of assessing 
putative culprit lesions that are at risk of rupture, and are consequentially liable to adverse 
outcomes.
Hypoxia has been consistently found in atherosclerotic plaques in vivo in humans and animal 
models using different biomarkers [55]. The immunologically identifiable hypoxia marker, 
7-(4˝-(2-nitroimidazole-1-yl)-butyl)-theophylline (NITP), has been used to assess hypoxia in 
three murine models in vivo. NITP can bind to cells under low-oxygen conditions [56, 57].
Other non-invasive imaging techniques have also been applied, which directly target plaque 
hypoxia, and these techniques are now being further validated in human studies. The met-
abolic marker F-fluorodeoxyglucose (FDG) has been used to detect human atherosclerosis 
in vivo and may also serve as an indirect marker of plaque hypoxia as the enhanced glu-
cose uptake in anaerobic metabolism results in an increased uptake of the labelled FDG 
[58]. F-18-fluoromisonidazole positron emission tomographic (PET) has been used for the in 
vivo assessment of hypoxia in advanced aortic atherosclerosis in rabbits where hypoxia has 
been found to be predominantly confined to the macrophage-rich regions within the ath-
eromatous core, whereas the macrophages close to the lumen were hypoxia negative [47]. 
This was then related to hypoxia assessed by ex vivo tissue staining using pimonidazole, and 
immuno-staining for macrophages (RAM-11), new vessels (CD31) and hypoxia-inducible 
factor-1 α. 18F-fluoromisonidazole (18F-FMISO), a cell permeable 2-nitroimidazole derivative 
that is reduced in vivo by nitroreductases, regardless of the intracellular oxygen concentra-
tion, has been one of the leading radiotracers for imaging hypoxia [47]. In human studies, 
this imaging approach has been coupled with quantitative polymerase chain reaction (qPCR) 
and immune-staining of plaques tissues recovered by carotid endarterectomy to determine 
the gene expression of HIF-1α and cluster of differentiation 68 (CD68, a marker of inflam-
mation). HIF-1α and CD68 expression were both found to be significantly correlated with 
F-FDG-uptake, indicating an association between the presence of hypoxia, inflammation and 
increased glucose metabolism in vivo [59].
Imaging plaque biomarkers such as CRP, interleukins 6, 10 and 18, soluble CD40 ligand, P- 
and E-selectin, NT-proBNP, fibrinogen and cystatin C show great potential in the prediction 
and improvement for vascular patients [60].
4.2. The development of a hypoxic environment within the atherosclerotic plaque
Hypoxia has been identified as a potential factor in the formation of vulnerable plaque, and 
it is clear that decreased oxygen plays a role in the development of plaque angiogenesis lead-
ing to plaque destabilization [61]. There have been a number of hypotheses of atherogenesis 
(plaque angiogenesis) proposing that an imbalance between the demand for and supply of 
oxygen in the arterial wall is a key factor in the development of atherosclerosis [2, 62].
During atherogenesis, the intima (the innermost layer of the artery wall) may thicken by the 
accumulation of cells and matrix, and the diffusion of oxygen can then become impaired. The 
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vasa vasorum, forming the network of small blood vessels, are vulnerable to hypoxia espe-
cially at the site of arterial branching as they are end arteries and the blood flow is reduced in 
this region. It has been hypothesized that hypoxia within the vasa vasorum is due to reduced 
blood flow and consequent endothelial dysfunction, local inflammation and permeation of 
large particles such as microbes, LDL-lipoprotein and fatty acids which are transformed by 
macrophages into foam cells [63, 64], which may be an initiating factor in atherosclerosis 
[65]. Therefore, the micro-environment within the atherosclerotic plaque is thought to be an 
important determinant of whether a plaque progresses, and the likelihood of clinical compli-
cations. Recent reports provide substantial evidence that there are regions within the plaque 
in which hypoxia can be identified [66].
In addition to being a marker of hypoxia, HIF-1α may directly enhance atherogenesis through 
several mechanisms, including smooth muscle cell proliferation and migration, new vessel 
formation (angiogenesis) and altered lipid metabolism [67]. The effects of HIF-1α on macro-
phage biology and subsequent promotion of atherogenesis has been studied in mice. HIF-1α 
expression in macrophages affects their intrinsic inflammatory profile and promotes the 
development of atherosclerosis [68]. Hence, HIF-1α may play a key role in the progression 
of atherosclerosis by initiating and promoting the formation of foam cells, endothelial cell 
dysfunction, apoptosis, increasing inflammation and angiogenesis [69].
It has been also proposed that the state of hypoxia, present in the atherosclerotic plaques of 
mice deficient in apolipoprotein E (ApoE−/− mice), may promote lipid synthesis, and reduce 
cholesterol efflux through the ATP-binding cassette transporter (ABCA1) pathway: processes 
that are known to be mediated by HIF-1α [55]. Hypoxia has also been reported to increase 
the formation of lipid droplets in macrophages to promote the secretion of inflammatory 
mediators, and atherosclerotic lesion progression by exacerbating ATP depletion and lactate 
accumulation in this model of atherosclerosis [53].
Several HIF-responsive genes have been found to be upregulated in atherosclerosis, such as 
VEGF, endothelin-1 and matrix-metalloproteinase-2 [70]. Hypoxia has the potential to fun-
damentally change the function, metabolism and responses of many of the cell types found 
within the developing atherosclerotic plaque, and this may in turn determine whether the 
plaque evolves into a stable or unstable phenotype. It is likely that this is mediated through 
effects on angiogenesis, extracellular matrix elaboration and lipoprotein metabolism. The 
hypoxic milieu in the atherosclerotic plaque may therefore also have implications for the 
putative therapeutic interventions for atherosclerosis. However, most in vitro studies have 
been conducted under normoxic conditions. The effects observed under these conditions may 
not accurately reflect those extant within the plaque [70].
The role of HIF-1 in atherosclerosis is not univocal. Silencing of HIF-1α in macrophages reduces 
proinflammatory factors and increases macrophage apoptosis. Hyperlipidaemia impairs 
angiogenesis in an HIF-1b and nuclear factor (NF)-κB-dependent manner. Specific knockdown 
of HIF-1α in endothelial cells reduces atherosclerosis through reduced monocyte recruitment 
[26], whereas knockdown in antigen-presenting cells results in aggravation of atherosclerosis 
through T-cell polarization [71]. There is another non-lipid-driven mechanism by which alter-
native macrophages present in human atherosclerosis M(Hb) promote plaque neoangiogenesis 
and microvessel incompetence throughan HIF-1α/VEGF-A-dependent pathway [72].
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HIF-1α has also been also implicated in the pathogenesis of in-stent restenosis following 
coronary revascularisation, stroke, peripheral artery disease, aortic aneurysm formation and 
pulmonary artery hypertension [73], and also appears to be involved in the calcification of 
blood vessels, which often accompanies atherosclerosis [74]. Despite being an intracellular 
transcription factor, HIF-1 could be possible released into the circulation from damaged cells, 
similar to other transcriptional factors such as NF-κB and p53 [74-76].
4.3. Other atherogenic mechanisms of hypoxia
Although plaque angiogenesis is a physiological response that facilitates the increased oxygen 
demand in the plaque, it can have adverse effects by facilitating intra-plaque haemorrhage 
(IPH) and the influx of inflammatory mediators. IPH as a result of immature plaque neovessels 
is associated with subsequent ischemic events. Inflammatory cell, endothelial cell and pericyte 
interactions can provide insight into the biological mechanisms of plaque angiogenesis [71].
The recruitment of T lymphocytes and proliferation and migration of smooth muscle and 
endothelial cells are essential for atherosclerotic plaque formation and development. During 
this process, a number of pro-inflammatory factors and cytokines, leukotrienes and chemo-
kines are increased in expression, especially in lipid-loaded foam cells, such as IL8, tumour 
necrosis factor α (TNFα), interleukin (IL)-1,vascular cell adhesion molecule 1 (VCAM-1) and 
15-lipoxygenase-2 (15-LOX-2). Moreover, macrophages are trapped in hypoxic areas of the 
lesion; however, the exact mechanisms have yet to be determined.
The majority of inflammatory cells contributing to early atherosclerosis probably enter the 
artery wall from the lumen [77, 78]. However, the vasa vasorum and associated microvessels 
may provide an alternate route by which leucocytes can enter the vascular wall [79]. As ath-
erosclerosis progresses, angiogenic factors within the micro-environment of the plaque may 
stimulate new vessel formation. This combination of delicate new vessel network and inflam-
matory cells, that elaborate proteolytic enzymes, may contribute to intra-plaque haemorrhage 
and subsequent plaque rupture [80]. The involvement of vasa vasorum and intimal hyper-
plasia in the pathophysiology of atherosclerosis is supported by several experimental animal 
studies [81, 82].
Hypoxia may also induce macrophage migration inhibitory factor (MIF). MIF plays a critical 
role in the progression of atherosclerosis by several different mechanisms. These include the 
MIF-triggered arrest and chemotaxis of monocytes and T cells through its receptors CXCR2/4. 
Further, in vivo studies have shown that the blockade of MIF in mice with advanced athero-
sclerosis leads to plaque regression and reduced monocyte and T-cell content. Additionally, 
the neuronal signalling molecule Netrin-1 was recently shown to play an important role 
in macrophage retention in atherosclerotic plaques. Notably, netrin-1 expression has been 
shown to be regulated by hypoxia, but this may be tissue or disease specific [55].
Atherosclerotic lesion formation is associated with vessel wall thickening resulting in 
regional limited oxygen exchange. Vascular cells respond to hypoxic conditions with 
changes in cell metabolism, angiogenesis, apoptosis and inflammatory responses compa-
rable to cells in tumours. Local hypoxic regions and hypoxic cells have been identified in 
human atherosclerotic lesions and in experimental models. Increased oxygen consumption 
by cells with a high metabolic activity, such as macrophages, further depletes the oxygen 
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availability, creating a hypoxic environment in the atherosclerotic lesion. In macrophages, 
hypoxia not only affects the metabolism and lipid uptake but also results in an increased 
inflammatory response characterized by increased IL-1β and caspase-1 activation. Hypoxia 
also augments the thrombogenic potential of atherosclerotic plaques through upregulation 
of tissue factor.
The identification of specific inflammatory markers pertaining to the arterial wall in ath-
erosclerosis may be useful for both diagnosis and treatment. These include macrophage 
inhibiting factor (MIF), leucocytes and P-selectin. Purinergic signalling is involved in the 
control of vascular tone and remodelling. Endothelial cells release purines and pyrimi-
dines in response to changes in blood flow (evoking shear stress) and hypoxia. They then 
act on P2Y, P2X and P1 receptors on endothelial cells leading to release of EDRF mediated 
by nitric oxide and prostaglandins and EDHF, resulting in vasodilatation. The therapeutic 
potential of purinergic compounds for the treatment of vascular diseases, including hyper-
tension, ischaemia, atherosclerosis, migraine and coronary artery and diabetic vascular 
disease as well as vasospasm is discussed [83]. Modern therapeutic modalities involv-
ing endothelial progenitor cells therapy, angiotensin II type-2 (AT2R) and ATP-activated 
purinergic receptor therapy are notable to mention. Future drugs may be designed to 
target three signalling mechanisms of AT2R which are (a) activation of protein phospha-
tases resulting in protein dephosphorylation, (b) activation of bradykinin/nitric oxide/
cyclic guanosine 3˝,5˝-monophosphate pathway by vasodilation and (c) stimulation of 
phospholipase A(2) and release of arachidonic acid. Drugs may also be designed to act on 
ATP-activated purinergic receptor channel type P2X7 molecules which acts on cardiovas-
cular system. Better understanding of the vascular inflammatory processes and the cells 
involved in the formation of plaques may prove to be beneficial for future diagnosis, clini-
cal treatment and planning innovative novel anti-atherosclerotic drugs [84].
Systemic hypoxia that is, for example, associated with obstructive sleep apnoea (OSA) 
also promotes atherosclerosis. The processes by which it may do this include effects on 
lipid metabolism and efflux, inflammation, altered macrophage polarization and glucose 
metabolism [85].
5. Conclusion
Hypoxia is involved in several pathophysiological processes, including embryogenesis, 
angiogenesis and atherogenesis. HIF-1 appears to be an important mediator controlling cel-
lular response to hypoxia. It also appears to be related to atherosclerotic progression and 
rupture. A better understanding of the mechanism involved in these processes may provide 
some novel therapeutic approaches to the treatment of cardiovascular disease.
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